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Drug-Induced Linear IgA Bullous Dermatosis
Luis Soro, D.O. and Tanya Ermolovich, D.O.
Lehigh Valley Health Network, Allentown, Pennsylvania and Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania

Case Presentation:
Patient: J.T. is a 61 year-old Caucasian male.
History of Present Illness: Patient presented to Lehigh Valley
Hospital with a several day history of a painful and pruritic rash that
began in his inguinal creases and had progressed to his back, abdomen,
buttocks, and upper and lower extremities. He was hospitalized 3 weeks
prior for an acutely painful ischemic left foot and gangrenous first toe
which resulted in femoral-peroneal bypass surgery. During that time
he received numerous antibiotics including vancomycin, piperacillin/
tazobactam, and levofloxacin. At the time of evaluation, vancomycin
was the only antibiotic being given. He denied any history of a similar
eruption in the past.
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Medical History: Peripheral vascular disease, HTN, DM type 2,
neuropathy, GERD, HSV1

1b

Current Medications: Vancomycin, fluconazole, gabapentin,
heparin, insulin (lispro and glargine), metoprolol, lisinopril, pantoprazole,
aspirin
Physical Examination: Numerous shallow ulcers with surrounding
erythema on the scrotum, penis, and perineum. Many flaccid vesicles
and bullae, some arranged in linear, arcuate and polycyclic patterns on
the trunk, buttocks and lower extremities. Small vesicles noted on the
lips. Pink thin blanchable plaques scattered on the trunk and extremities.
Laboratory Data: CBC (8/29/12): WBC: 14.2 (4.5-11 thou/cmm),
neutrophils 82% (40-70%), lymphocytes 9% (20-44%); Hgb: 11.2
(13.5-18.0 g/dL); Hct: 33 (40-54%); Plt: 459 (140-350 thou/cmm); CMP
(8/29/12): WNL.
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Figures 1a-1c: Many vesicles and bullae. Some are arranged in arcuate and annular patterns, others in a more linear
configuration, particularly adjacent to the scar from recent femoral-peroneal bypass surgery.
Figures 2a-2b: Subepidermal bullous process with neutrophils lining up along the dermal-epidermal junction.

ANA profile, serum BP180 and BP230 autoantibodies, and serum
transglutaminase IgA autoantibodies were ordered but not obtained by
the patient.
Studies: Blood Cx (8/29/12): negative, MRSA screen (8/30/12):
negative, HSV Cx lip (8/30/12): negative.
Biopsy: Health Network Laboratories (S12-23570, 8/30/12)
Right posterior proximal arm: “Subepidermal bullous process with
predominance of neutrophils. There is extensive dermoepidermal
separation with neutrophils noted to line up along the DE junction in a
band-like configuration. There is an underlying superficial perivascular
inflammatory infiltrate consisting predominantly of neutrophils admixed
with few eosinophils.”
Direct immunofluorescence: Mayo Medical Laboratories (IR124235, 8/30/12) Right posterior arm: “IgA: Strong discontinuous linear
basement membrane zone, IgG: Strong discontinuous linear basement
membrane zone, C3: Continuous linear basement membrane zone, IgM:
Negative”
Treatment: Discontinued vancomycin. Triamcinolone 0.1% cream
applied BID to affected areas. Triple paste barrier cream applied to
ulcerations on buttocks. White petrolatum jelly to superficial ulcers.
Response: Patient ceased to develop further vesiculobullous lesions
and experienced resolution of his ulcerations within 3 weeks following
conservative treatment with topical emollients. All his other medications
were continued during this period.

Discussion:

Linear IgA bullous dermatosis is an uncommon autoimmune blistering disorder in which IgA antibodies are directed against antigens in the basement membrane zone
(BMZ) of the skin and mucosa. The most commonly identified antigens are proteolytic cleavage products of the hemidesmosomal protein BP180 and include a 97-kDa
(LABD-97) antigen and 120-kDa (LAD-1) antigen. IgA binding to these sites, subsequent complement activation, inflammatory cell recruitment, and release of proteolytic
enzymes lead to disruption of the BMZ and ultimately epithelial-dermal detachment. The resulting clinical lesions appear as clear or hemorrhagic vesicles and bullae of
varying sizes that may coalesce to form annular or polycyclic arrangements – the so-called “cluster of jewels” pattern. Pruritic urticarial plaques may occur alongside the
vesiculobullous lesions.
Linear IgA may be idiopathic or secondary to precipitating factors including drugs and, less frequently, systemic disease, trauma, or ultraviolet light. The drug-induced
form is reported to occur anywhere between 24 hours to 29 days following administration of the medication. Vancomycin is the most commonly associated drug followed
by amiodarone, diclofenac, captopril, ceftriaxone-metronidazole, naproxen, piroxicam, and phenytoin. The pathophysiologic mechanism behind drug-induced linear IgA
is unclear but it is suggested that the offending medication may cross-react with autoantigens of the BMZ and change their conformational structure or perhaps unmask
antigens previously hidden from the immune system[1].
Biopsies of early lesions reveal subepidermal bullae with a predominantly neutrophilic infiltrate. Direct immunofluorescence (DIF) facilitates the diagnosis by
demonstrating a linear pattern of IgA deposition along the BMZ. This is in contrast to the granular deposits of IgA seen in the papillary dermis in dermatitis herpetiformis.
Deposits of C3 complement accompany IgA in most instances. Linear IgG or IgM deposits are also commonly involved along the BMZ. One study reported that IgG, IgM,
and complement were seen in 20/31 cases[2]. Because bullous pemphigoid (BP) may also show linear IgG, C3, and IgA on DIF, differentiation can be problematic. BP
usually involves a higher concentration of IgG over IgA and a more eosinophilic infiltrate on H&E. In these cases, clinocopathological correlation is necessary.
Drug-induced linear IgA bullous dermatosis has a very good prognosis, typically resolving within 2-6 weeks after discontinuation of the offending medication. Treatment
includes topical corticosteroids in mild disease either as a sole agent or an adjunct to systemic therapy. The first line systemic agent for more involved disease is dapsone
followed by sulfapyridine. Systemic corticosteroids and other immunosuppressive agents such as mycophenolic acid and cyclosporine can be helpful in patients not
adequately controlled with first or second line medications. Dicloxacillin, erythromycin, and trimethoprim-sulfamethoxazole have been shown to be highly effective as
well. Ulcerations may be treated with topical barrier creams and emollients to expedite healing.

Diagnosis: Linear IgA bullous dermatosis likely secondary to
vancomycin
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